Chris Jones is an experienced patent litigator that focuses his practice on Hatch-Waxman and life sciences patent litigation. Chris has developed a deep understanding of the Hatch-Waxman litigation process and has litigated cases involving Abbreviated New Drug Applications (ANDAs), 505(b)(2) applications (sometimes referred to as “paper NDAs”), and more. He has experience at all stages of Hatch-Waxman cases and has litigated cases through trial both in United States District Courts and at the Patent Trial and Appeal Board (PTAB). Chris also has experience advising clients on the Food and Drug Administration (FDA) approval process, and understands the importance of balancing the complexities of FDA regulatory and patent litigation issues.
Chris has a diverse background in chemical and biochemical technologies, including pharmaceutical chemistry, organic chemistry, solid-state chemistry, biochemistry, polymer chemistry and cell biology. As a graduate student, his research focused on drug development and formulation, specifically the development and characterization of solid and crystalline forms of new and existing drug compounds. Prior to graduate school, Chris performed research projects related to the synthesis and characterization of polymers, organic compounds useful in the field of agricultural chemistry and also worked in a cell biology laboratory on the development of cancer therapies.
While earning his J.D. at George Mason University School of Law, Chris worked as a patent agent and technology specialist, where he used his background in chemistry to assist patent attorneys with opinion preparation and patent prosecution matters. He was a member of the Intellectual Property Law Society and graduated with a concentration in intellectual property law.
